Header Logo

Connection

Naoko Takebe to Humans

Back to Details
This is a "connection" page, showing publications Naoko Takebe has written about Humans.
Naoko Takebe
Connection Strength
1.707
Humans
  1. Blood-based multi-cancer detection: A state-of-the-art update. Curr Probl Cancer. 2024 02; 48:101059.
    View in: PubMed
    Score: 0.052
  2. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet. 2022 08 13; 400(10351):512-521.
    View in: PubMed
    Score: 0.047
  3. Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. J Clin Oncol. 2022 06 10; 40(17):1949-1957.
    View in: PubMed
    Score: 0.046
  4. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):3834-3844.
    View in: PubMed
    Score: 0.043
  5. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2020 04; 17(4):204-232.
    View in: PubMed
    Score: 0.039
  6. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. Br J Clin Pharmacol. 2019 11; 85(11):2499-2511.
    View in: PubMed
    Score: 0.038
  7. Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine. Cancer J. 2019 Jul/Aug; 25(4):296-299.
    View in: PubMed
    Score: 0.038
  8. Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy?in Cancer Therapy Evaluation Program-sponsored phase I trials. Eur J Cancer. 2019 07; 115:111-119.
    View in: PubMed
    Score: 0.038
  9. A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. Clin Pharmacol Ther. 2019 10; 106(4):803-809.
    View in: PubMed
    Score: 0.037
  10. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. Cancer Sci. 2018 Jan; 109(1):207-214.
    View in: PubMed
    Score: 0.034
  11. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience. Curr Probl Cancer. 2017 May - Jun; 41(3):201-211.
    View in: PubMed
    Score: 0.033
  12. Precision medicine in oncology. Curr Probl Cancer. 2017 May - Jun; 41(3):163-165.
    View in: PubMed
    Score: 0.032
  13. Drug induced interstitial lung disease in oncology phase?I trials. Cancer Sci. 2016 Dec; 107(12):1830-1836.
    View in: PubMed
    Score: 0.032
  14. Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials. Gastric Cancer. 2017 May; 20(3):481-488.
    View in: PubMed
    Score: 0.031
  15. Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration. Semin Radiat Oncol. 2016 10; 26(4):271-80.
    View in: PubMed
    Score: 0.031
  16. Sonic hedgehog signaling pathway and gallbladder cancer: targeting with precision medicine approach. Chin Clin Oncol. 2016 Feb; 5(1):1.
    View in: PubMed
    Score: 0.030
  17. Perspectives on research activity in the USA on Cancer Precision Medicine. Jpn J Clin Oncol. 2016 Feb; 46(2):106-10.
    View in: PubMed
    Score: 0.029
  18. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development. Jpn J Clin Oncol. 2015 Nov; 45(11):1001-6.
    View in: PubMed
    Score: 0.029
  19. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015 Aug; 12(8):445-64.
    View in: PubMed
    Score: 0.028
  20. Biomarkers: exceptional responders-discovering predictive biomarkers. Nat Rev Clin Oncol. 2015 Mar; 12(3):132-4.
    View in: PubMed
    Score: 0.028
  21. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014 Feb; 141(2):140-9.
    View in: PubMed
    Score: 0.025
  22. International models of investigator-initiated trials: implications for Japan. Ann Oncol. 2012 Dec; 23(12):3151-3155.
    View in: PubMed
    Score: 0.023
  23. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res. 2011 Jun 10; 13(3):211.
    View in: PubMed
    Score: 0.022
  24. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011 Feb; 8(2):97-106.
    View in: PubMed
    Score: 0.021
  25. Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin Cancer Res. 2010 Jun 15; 16(12):3106-12.
    View in: PubMed
    Score: 0.020
  26. Preliminary findings on the use of pulsatile machine reperfusion of a placenta to improve the cord blood collection yield including primitive hematopoietic stem cell fractions. Transfusion. 2009 Sep; 49(9):1911-6.
    View in: PubMed
    Score: 0.019
  27. Human brain endothelial cells (HUBEC) promote SCID repopulating cell expansion through direct contact. Growth Factors. 2007 Jun; 25(3):141-50.
    View in: PubMed
    Score: 0.016
  28. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther. 2006 Feb; 5(2):457-66.
    View in: PubMed
    Score: 0.015
  29. Multiple myeloma presenting initially as a solitary pleural effusion later complicated by malignant plasmacytic ascites. Leuk Res. 2005 Jun; 29(6):715-8.
    View in: PubMed
    Score: 0.014
  30. Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U. JCO Precis Oncol. 2024 Dec; 8:e2400327.
    View in: PubMed
    Score: 0.014
  31. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin Cancer Res. 2004 Dec 15; 10(24):8301-8.
    View in: PubMed
    Score: 0.014
  32. Current landscape of targeted therapy in esophageal squamous cell carcinoma. Curr Probl Cancer. 2024 Dec; 53:101152.
    View in: PubMed
    Score: 0.014
  33. A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples. Cancer Res Commun. 2024 09 01; 4(9):2384-2398.
    View in: PubMed
    Score: 0.014
  34. Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. JCO Precis Oncol. 2024 Sep; 8:e2400258.
    View in: PubMed
    Score: 0.014
  35. Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). JCO Precis Oncol. 2024 Sep; 8:e2400418.
    View in: PubMed
    Score: 0.014
  36. Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. Oncologist. 2024 Aug 05; 29(8):723-e1093.
    View in: PubMed
    Score: 0.013
  37. Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT. Clin Cancer Res. 2024 Aug 01; 30(15):3167-3178.
    View in: PubMed
    Score: 0.013
  38. Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4. Cancer Res Commun. 2024 08 01; 4(8):2101-2111.
    View in: PubMed
    Score: 0.013
  39. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. Oncologist. 2024 Jul 05; 29(7):638-e952.
    View in: PubMed
    Score: 0.013
  40. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol. 2024 Aug; 21(8):610-627.
    View in: PubMed
    Score: 0.013
  41. The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs. Mol Cancer Ther. 2024 Jul 02; 23(7):911-923.
    View in: PubMed
    Score: 0.013
  42. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Res Commun. 2024 07 01; 4(7):1793-1801.
    View in: PubMed
    Score: 0.013
  43. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103.
    View in: PubMed
    Score: 0.013
  44. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clin Cancer Res. 2024 May 01; 30(9):1739-1749.
    View in: PubMed
    Score: 0.013
  45. Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts. Cancer Res Commun. 2024 03 19; 4(3):834-848.
    View in: PubMed
    Score: 0.013
  46. The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers. Cancer Chemother Pharmacol. 2024 Aug; 94(2):157-167.
    View in: PubMed
    Score: 0.013
  47. Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2024 Feb; 8:e2300371.
    View in: PubMed
    Score: 0.013
  48. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. Invest New Drugs. 2024 Feb; 42(1):127-135.
    View in: PubMed
    Score: 0.013
  49. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363.
    View in: PubMed
    Score: 0.013
  50. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. N Engl J Med. 2023 Sep 07; 389(10):911-921.
    View in: PubMed
    Score: 0.013
  51. The NCI-MATCH trial: lessons for precision oncology. Nat Med. 2023 Jun; 29(6):1349-1357.
    View in: PubMed
    Score: 0.012
  52. Rethinking Oncologic Treatment Strategies with Interleukin-2. Cells. 2023 05 05; 12(9).
    View in: PubMed
    Score: 0.012
  53. Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. Clin Cancer Res. 2023 04 03; 29(7):1200-1208.
    View in: PubMed
    Score: 0.012
  54. ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449. J Neurooncol. 2023 Jan; 161(1):33-43.
    View in: PubMed
    Score: 0.012
  55. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734.
    View in: PubMed
    Score: 0.012
  56. Population Pharmacokinetics of Z-Endoxifen?in Patients With Advanced Solid Tumors. J Clin Pharmacol. 2022 09; 62(9):1121-1131.
    View in: PubMed
    Score: 0.012
  57. A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma. Clin Cancer Res. 2022 04 14; 28(8):1586-1594.
    View in: PubMed
    Score: 0.011
  58. Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2235-2245.
    View in: PubMed
    Score: 0.011
  59. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2224-2234.
    View in: PubMed
    Score: 0.011
  60. Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene. Cancer Gene Ther. 2002 Mar; 9(3):308-20.
    View in: PubMed
    Score: 0.011
  61. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther. 2001 Dec; 8(12):966-73.
    View in: PubMed
    Score: 0.011
  62. Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas. Clin Cancer Res. 2022 01 15; 28(2):279-288.
    View in: PubMed
    Score: 0.011
  63. SMAC Mimetic/IAP Inhibitor Birinapant Enhances Radiosensitivity of Glioblastoma Multiforme. Radiat Res. 2021 06 01; 195(6):549-560.
    View in: PubMed
    Score: 0.011
  64. SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243. Cancer Res. 2021 06 01; 81(11):3067-3078.
    View in: PubMed
    Score: 0.011
  65. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst. 2021 01 04; 113(1):27-37.
    View in: PubMed
    Score: 0.011
  66. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Mol Ther. 2001 Jan; 3(1):88-96.
    View in: PubMed
    Score: 0.011
  67. Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res. 2021 03 15; 27(6):1604-1611.
    View in: PubMed
    Score: 0.011
  68. The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. Hum Vaccin Immunother. 2021 07 03; 17(7):1935-1939.
    View in: PubMed
    Score: 0.010
  69. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell. 2021 01 11; 39(1):38-53.e7.
    View in: PubMed
    Score: 0.010
  70. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020 11 20; 38(33):3883-3894.
    View in: PubMed
    Score: 0.010
  71. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020 10 01; 112(10):1021-1029.
    View in: PubMed
    Score: 0.010
  72. Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectors. Cancer Gene Ther. 2000 Jun; 7(6):910-9.
    View in: PubMed
    Score: 0.010
  73. A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. Invest New Drugs. 2020 06; 38(3):855-865.
    View in: PubMed
    Score: 0.010
  74. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. PLoS One. 2018; 13(6):e0199361.
    View in: PubMed
    Score: 0.009
  75. Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients. J Interferon Cytokine Res. 1998 May; 18(5):321-6.
    View in: PubMed
    Score: 0.009
  76. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs. 2018 06; 36(3):442-450.
    View in: PubMed
    Score: 0.008
  77. Drug delivery of oral anti-cancer fluoropyrimidine agents. Expert Opin Drug Deliv. 2017 12; 14(12):1355-1366.
    View in: PubMed
    Score: 0.008
  78. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. Curr Probl Cancer. 2017 May - Jun; 41(3):182-193.
    View in: PubMed
    Score: 0.008
  79. Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017 May - Jun; 41(3):194-200.
    View in: PubMed
    Score: 0.008
  80. Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clin Cancer Res. 2017 Jun 15; 23(12):2972-2980.
    View in: PubMed
    Score: 0.008
  81. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. 2016 Aug 01; 122(15):2371-8.
    View in: PubMed
    Score: 0.008
  82. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clin Cancer Res. 2016 Oct 01; 22(19):4786-4796.
    View in: PubMed
    Score: 0.008
  83. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.
    View in: PubMed
    Score: 0.007
  84. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer. 2016 Feb 15; 122(4):588-597.
    View in: PubMed
    Score: 0.007
  85. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
    View in: PubMed
    Score: 0.007
  86. Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use. Clin Cancer Res. 2016 Feb 15; 22(4):1000-10.
    View in: PubMed
    Score: 0.007
  87. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015 Aug 20; 33(24):2646-54.
    View in: PubMed
    Score: 0.007
  88. Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(12):3336-42.
    View in: PubMed
    Score: 0.007
  89. Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Jun; 21(6):1083-90.
    View in: PubMed
    Score: 0.007
  90. Notch1 phenotype and clinical stage progression in non-small cell lung cancer. J Hematol Oncol. 2015 Feb 06; 8:9.
    View in: PubMed
    Score: 0.007
  91. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014 Dec 01; 20(23):5937-5945.
    View in: PubMed
    Score: 0.007
  92. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia. Am J Hematol. 2014 Sep; 89(9):896-903.
    View in: PubMed
    Score: 0.007
  93. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs. 2014 Oct; 32(5):1005-16.
    View in: PubMed
    Score: 0.007
  94. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014; 71-6.
    View in: PubMed
    Score: 0.006
  95. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann Oncol. 2013 Nov; 24(11):2922-6.
    View in: PubMed
    Score: 0.006
  96. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013 Nov 15; 19(22):6305-12.
    View in: PubMed
    Score: 0.006
  97. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest New Drugs. 2014 Apr; 32(2):295-302.
    View in: PubMed
    Score: 0.006
  98. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
    View in: PubMed
    Score: 0.006
  99. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst. 2013 Jan 02; 105(1):11-24.
    View in: PubMed
    Score: 0.006
  100. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner. J Biol Chem. 2012 Jun 22; 287(26):22408-17.
    View in: PubMed
    Score: 0.006
  101. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 08; 305(22):2327-34.
    View in: PubMed
    Score: 0.005
  102. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):481-5.
    View in: PubMed
    Score: 0.005
  103. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011 Feb 15; 17(4):654-66.
    View in: PubMed
    Score: 0.005
  104. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. 2011 May 15; 117(10):2112-9.
    View in: PubMed
    Score: 0.005
  105. Molecular conversations and the development of the hair follicle and basal cell carcinoma. Cancer Prev Res (Phila). 2010 Oct; 3(10):1217-21.
    View in: PubMed
    Score: 0.005
  106. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15.
    View in: PubMed
    Score: 0.005
  107. Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan. Nat Rev Clin Oncol. 2010 Mar; 7(3):127-8.
    View in: PubMed
    Score: 0.005
  108. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1079-85.
    View in: PubMed
    Score: 0.005
  109. NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide. Gynecol Oncol. 2010 Feb; 116(2):177-80.
    View in: PubMed
    Score: 0.005
  110. Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res. 2007 Sep; 31(9):1165-73.
    View in: PubMed
    Score: 0.004
  111. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant. 2006 Jan; 37(1):65-72.
    View in: PubMed
    Score: 0.004
  112. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol. 2005 Jun 20; 23(18):4089-99.
    View in: PubMed
    Score: 0.004
  113. Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene. Cancer Gene Ther. 2004 Dec; 11(12):767-73.
    View in: PubMed
    Score: 0.003
  114. Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 Nov; 34(10):883-90.
    View in: PubMed
    Score: 0.003
  115. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant. 2004 Jul; 34(1):69-76.
    View in: PubMed
    Score: 0.003
  116. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant. 2004 Jul; 10(7):473-83.
    View in: PubMed
    Score: 0.003
  117. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant. 2004 Apr; 33(8):781-7.
    View in: PubMed
    Score: 0.003
  118. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res. 2003 Jan; 9(1):223-7.
    View in: PubMed
    Score: 0.003
  119. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant. 2002 Feb; 29(4):303-12.
    View in: PubMed
    Score: 0.003
  120. Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene. Gynecol Oncol. 2000 Mar; 76(3):305-10.
    View in: PubMed
    Score: 0.002
  121. Protection of bone marrow cells from toxicity of chemotherapeutic agents targeted toward thymidylate synthase by transfer of mutant forms of human thymidylate synthase cDNA. Prog Exp Tumor Res. 1999; 36:107-14.
    View in: PubMed
    Score: 0.002
  122. Nucleotide sequences of cDNAs for human papillomavirus type 18 transcripts in HeLa cells. J Virol. 1988 May; 62(5):1640-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.